This web app uses cookies to compile statistic information of our users visits. By continuing to browse the site you are agreeing to our use of cookies. If you wish you may change your preference or read about cookies

close

Why Novartis's Business Model is so successful?

Get all the answers

Embed code:

x
Copy the code below and embed it in yours to show this business model canvas in your website.

Novartis’s Company Overview


Novartis AG is a global healthcare company dedicated to transforming the future of medicine. Headquartered in Switzerland, Novartis operates at the forefront of research, development, manufacturing, and marketing of a broad spectrum of healthcare products, with a strong emphasis on innovative pharmaceuticals. The company’s mission is to improve and extend people’s lives by unleashing the power of science to address pressing medical needs. Novartis operates through several key segments, including Innovative Medicines, Sandoz, and its former division, Alcon, which was spun off in 2019 to become an independent company focusing on eye care.

Novartis' business model is centered on driving meaningful innovation by investing heavily in research and development. The Innovative Medicines segment is dedicated to the discovery and commercialization of newly patented prescription drugs aimed at treating a wide range of diseases and conditions. The Sandoz division complements this by focusing on generic pharmaceuticals and biosimilars, which offer more affordable treatment options across various therapeutic areas. By maintaining a balance between cutting-edge patented medications and cost-effective generics, Novartis is uniquely positioned to enhance health outcomes while making high-quality healthcare accessible to a larger population globally. In addition, strategic collaborations and partnerships with biotech firms and academic institutions further strengthen Novartis’ innovative capability.

The revenue model of Novartis is multi-faceted and robust, designed to ensure sustainable growth and profitability. The majority of the company’s revenue is generated through the sales of its diverse portfolio of pharmaceuticals, including both branded innovative drugs and generics. With its strong global presence, Novartis leverages extensive distribution networks to reach a broad array of markets. Sandoz contributes significantly to the revenue stream by serving high-demand markets for generics and biosimilars. Moreover, the company engages in strategic licensing agreements and collaborations that supplement its income and expand its research horizons. This diversified approach to revenue generation enables Novartis to navigate market dynamics effectively and maintain a leading position in the ever-evolving healthcare industry.

www.novartis.com

Headquater: Basel, Switzerland, Europe

Foundations date: 1996

Company Type: Public

Sector: Healthcare

Category: Pharmaceuticals

Digital Maturity: Beginner


Novartis’s Related Competitors



Novartis’s Business Model Canvas


Novartis’s Key Partners
  • Healthcare Providers
  • Research Institutions
  • Universities
  • Biotech Firms
  • Government Agencies
  • Regulatory Bodies
  • Contract Research Organizations (CROs)
  • Pharmaceutical Distributors
  • Industry Associations
  • Technology Providers
Novartis’s Key Activities
  • Research and Development
  • Clinical Trials
  • Manufacturing
  • Regulatory Affairs
  • Sales and Marketing
  • Product Distribution
  • Quality Control
  • Patient Support Services
  • Strategic Partnerships
  • Market Analysis
Novartis’s Key Resources
  • Patents and Intellectual Property
  • Research and Development Facilities
  • Strategic Partnerships
  • Skilled Workforce
  • Brand Reputation
  • Financial Capital
  • Advanced Technology and Equipment
  • Regulatory Approvals
Novartis’s Value Propositions
  • Innovative pharmaceutical solutions
  • Cutting-edge research and development
  • Advanced therapies for complex diseases
  • Personalized medicine
  • Patient-centric healthcare solutions
  • High-quality generic medicines
  • AI-driven drug discovery
  • Sustainable healthcare development
  • Global health initiatives
  • Trusted medical expertise
  • Comprehensive treatment options
  • Efficient drug delivery systems
Novartis’s Customer Relationships
  • Personalized Medicine
  • Patient Support Programs
  • Key Account Management
  • Healthcare Professionals Engagement
  • Digital Health Tools
  • Community Outreach Programs
  • Direct-to-Consumer Advertising
  • Specialized Customer Service
  • Collaborative Partnerships
  • Medical Conferences and Workshops
Novartis’s Customer Segments
  • Patients
  • Healthcare Providers
  • Hospitals and Clinics
  • Government Health Agencies
  • Health Insurance Companies
  • Research Institutions
  • Nonprofit Organizations
  • Pharmaceutical Distributors
  • Retail Pharmacies
Novartis’s Channels
  • Direct Sales
  • Distributors
  • E-commerce Platform
  • Online Pharmaceutical Portals
  • Partnership with Hospitals
  • Telemedicine Platforms
  • Sales Force
  • Pharmacies and Drugstores
  • Medical Conferences and Trade Shows
  • Healthcare Providers
Novartis’s Cost Structure
  • Research and Development Costs
  • Manufacturing and Production Costs
  • Marketing and Sales Expenses
  • Distribution and Logistics Costs
  • Administrative and General Expenses
  • Regulatory Compliance Costs
  • Licensing and Royalty Payments
  • Technology and IT Infrastructure Costs
  • Employee Salaries and Benefits
  • Facility and Maintenance Costs
  • Supply Chain Management Expenses
  • Legal and Patent Expenses
  • Clinical Trial Costs
Novartis’s Revenue Streams
  • Product Sales
  • Licensing Fees
  • Research Funding
  • Partnership Income

Vizologi

A generative AI business strategy tool to create business plans in 1 minute

FREE 7 days trial ‐ Get started in seconds

Try it free

Novartis’s Revenue Model


Novartis makes money by combining different business models. Below, you will find the list of the different monetization strategies identified for this company:

  • Cross-subsidiary
  • White label
  • Lock-in
  • Biopharma
  • Low touch
  • Licensing
  • Healthcare
  • Make and distribute
  • Regular replacement
  • Decomposition
Analytics


Market Overview
  • Patterns
  • Sectors
  • Categories
  • Companies
  • Right click on the nodes to explore

Novartis’s Case Study


Novartis's CASE STUDY

At Novartis, we find ourselves at the confluence of scientific innovation and impactful healthcare solutions, uniquely equipped to address some of the world's most pressing medical needs. As a global healthcare company headquartered in Switzerland, we are dedicated to transforming the future of medicine, making high-quality healthcare accessible to a larger population worldwide.

Our Journey at Novartis

Our story began in 1996, yet our roots in healthcare and pharmaceuticals stretch much longer, back to the 18th century. Over time, through countless mergers and acquisitions, we have embraced innovation as our core value. This commitment has culminated in a company that is built around three segments: Innovative Medicines, Sandoz, and the former Alcon division, which has since been spun off to focus specifically on eye care.

Transforming Lives Through Innovative Medicines

Our Innovative Medicines division is the heartbeat of our company. We take pride in discovering and commercializing newly patented prescription drugs designed to treat a wide array of diseases and conditions. The value proposition here is clear: We strive to provide cutting-edge therapies that transform lives. A defibrillator in our mission to improve lives has been our investment in research and development. According to our 2022 financial reports, Novartis allocated approximately $9.1 billion to R&D, which represents around 20% of our total revenue (Novartis Annual Report, 2022). Think about that for a moment. It’s not just money—it's a commitment to hope, wellness, and therapeutic advancements for people around the world.

The Uniqueness of Sandoz

If our Innovative Medicines segment is the heartbeat, Sandoz is the steady pulse that keeps the organization resilient and diverse. Focusing on generic pharmaceuticals and biosimilars, Sandoz brings more affordable treatment options to many. This segment is vital in ensuring that healthcare remains within reach for broader populations, especially in under-served markets. One key metric illustrating Sandoz's impact is its operational efficiency. In 2022, Sandoz accounted for 22% of Novartis' net sales, reinforcing the balanced nature of our revenue streams (Novartis Annual Report, 2022). The division thrives on the principle of bringing high-quality, cost-effective generic medications that still adhere to meticulous standards.

Strategic Collaborations and Partnerships

What sets Novartis apart from others is our robust ecosystem of partnerships. These partnerships extend to healthcare providers, research institutions, biotech firms, and government agencies. A noteworthy collaboration has been with the Broad Institute of MIT and Harvard. Together, we have engaged in numerous initiatives that marry the prowess of advanced biology with cutting-edge technology to develop next-generation treatments. For example, our collaboration on the CRISPR genome-editing project has propelled us to the forefront of genetic research (Harvard Business Review, 2022). Such strategic alliances only bolster our core mission to unleash the power of science.

Sustainable Revenue Streams

Our multi-faceted revenue model ensures sustainable growth. Here, product sales stand as the most substantial segment. However, we also rely on licensing fees, research funding, and partnership income to maintain financial health. In 2022, net sales from Innovative Medicines reached approximately $36.7 billion, contributing to 74% of the company's total net sales (Novartis Annual Report, 2022). The revenue generated from our diverse portfolio—ranging from cutting-edge pharmaceuticals to cost-effective generics—enables us to navigate market dynamics effectively.

Customer-Centric Approach

Our customer relationships are deeply rooted in understanding and addressing a spectrum of needs. From emotional aspects like reducing anxiety and improving wellness, to functional necessities such as risk reduction and hassle avoidance, our approach is comprehensive. We leverage various channels to reach our diverse customer segments—patients, healthcare providers, hospitals, and government agencies. Our patient support programs are a testament to this commitment. For instance, our Global Health & Corporate Responsibility initiatives have positively impacted over 20 million patients in low and middle-income countries through access to essential medicines and healthcare services annually (World Health Organization, 2022).

Operational Efficiency

Efficiency in our operations isn't just an internal goal; it’s a patient necessity. Our activities span from research and development to clinical trials and regulatory affairs. The effectiveness of these operations is evidenced by our remarkable record in regulatory approvals. Consider this: In 2022, we secured 13 major drug approvals worldwide, allowing us to bring new treatments to market faster and more economically (Novartis Annual Report, 2022).

The Future of Healthcare

Looking ahead, we are leaning into digital transformation to enhance our competitive edge. Artificial intelligence and machine learning are significantly cutting down the time required for drug discovery. AI-driven platforms have enabled us to sift through petabytes of data to streamline the drug discovery process. We are focused on patient-centric healthcare solutions. Personalized medicine and advanced therapies for complex diseases are no longer futuristic aspirations—they are our present reality. Enhanced with AI and machine learning technologies, we’re on the precipice of a new era in healthcare. Given our strategic vision, deep-rooted expertise, and unyielding dedication to innovation, Novartis continues to stand resilient and relevant. By maintaining a unique balance between innovative drugs and cost-effective generics, expanding strategic collaborations, and leaning into transformative technologies, we are well-positioned to navigate the ever-evolving landscape of global healthcare. Our journey is grounded in a simple yet powerful aspiration: to improve and extend lives by unlocking the power of science. From Basel to the world, we remain steadfast in this mission—because at Novartis, transforming the future of medicine is not just a business; it’s a commitment to humanity.


If you enjoyed this content, you’re in for a treat! Dive into our extensive repository of business model examples, where we’ve dissected and analyzed thousands of business strategies from top tech companies and innovative startups. Don’t miss out!

+100 Business Book Summaries

We've distilled the wisdom of influential business books for you.

Zero to One by Peter Thiel.
The Infinite Game by Simon Sinek.
Blue Ocean Strategy by W. Chan.